NCT04638829View on ClinicalTrials.gov

Safety and Treatment Satisfaction in Adults With Chronic ITP After Switching to Avatrombopag From Eltrombopag or Romiplostim

PHASE4CompletedINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

March 15, 2021

Primary Completion Date

January 3, 2024

Study Completion Date

January 3, 2024

Conditions
Immune Thrombocytopenia
Interventions
DRUG

Avatrombopag Oral Tablet

Avatrombopag 20 mg given daily for 90 days. Initial dose and dose adjustments will be determined by the physician along with the Doptelet prescribing information

Trial Locations (20)

17403

Sobi Site 102, York

19104

Sobi Site 127, Philadelphia

20010

Sobi Site 123, Washington D.C.

20817

Sobi Site 101, Bethesda

27514

Sobi Site 121, Chapel Hill

27834

Sobi Site 116, Greenville

29732

Sobi Site 104, Rock Hill

33143

Sobi Site 129, Miami

33606

Sobi Site 118, Tampa

33709

Sobi Site 125, St. Petersburg

34474

Sobi Site 120, Ocala

44106

Sobi Site 128, Cleveland

60612

Sobi Site 126, Chicago

61614

Sobi Site 109, Peoria

68506

Sobi Site 103, Lincoln

70112

Sobi Site 124, New Orleans

75246

Sobi Site 113, Dallas

84132

Sobi Site 108, Salt Lake City

85745

Sobi Site 110, Tucson

90603

Sobi Site 119, Whittier

All Listed Sponsors
lead

Sobi, Inc.

INDUSTRY

NCT04638829 - Safety and Treatment Satisfaction in Adults With Chronic ITP After Switching to Avatrombopag From Eltrombopag or Romiplostim | Biotech Hunter | Biotech Hunter